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Respiratory failure is a major cause of mortality among hospitalized patients with COVID-19 (1). Previous 
studies have shown that right ventricular (RV) dilation and reduced RV longitudinal strain are markers of poor 
outcome in this disease (2,3). COVID-19 can cause direct myocardial injury resulting in left ventricular (LV) systolic 
dysfunction and heart failure suggesting that assessment of LV function might also have prognostic value (4). 
Reduction of longitudinal systolic function assessed by mitral annular plane systolic excursion (MAPSE) is an early 
indicator of myocardial disease in various cardiac disorders (5). In this retrospective study, we investigated the 
prognostic value of MAPSE in patients admitted with respiratory failure related to COVID-19 infection. 
 One-hundred and nine patients were admitted to the ICU at IU Health hospitals with lab confirmed severe 
COVID-19 infections, defined as SpO2<94%, respiratory rate≥30 breaths per minute and P/F ratio ≤300 mmHg or 
need for mechanical ventilation. Of these, 68 patients that underwent transthoracic echocardiogram (TTE) based on 
clinical indication were included in the final analysis. Echocardiograms were performed using GE S70 and E95 (GE 
Healthcare, Milwaukee, Wisconsin, USA) and Phillips EPIQ (Philips Medical Systems, Andover, MA, USA) ultrasound 
systems. Images were acquired according to a limited COVID-19 protocol and measurements were performed as per 
American Society of Echocardiography guidelines. LV ejection fraction (EF) was measured by biplane Simpson’s 
method. MAPSE was calculated as the average of septal and lateral mitral annular excursion measured in the apical 
4-chamber view. Thirty-five of the 68 studies (52%) had sub-optimal image quality. 
 TTE was performed a median of 1 day (Inter-quartile range, 0-3 days) after hospital admission. Sixty-six 
patients (97%) required mechanical ventilation during hospitalization. Of these, 52 (79%) were on a ventilator at the 
time of echocardiography. Twenty-two patients (32%) died during hospitalization. Chi-square and Mann-Whitney U 
tests were used to compare clinical characteristics between survivors and those who died (Table 1).  P-values <0.05 
was considered significant. Increased age (p=0.018) and shock requiring vasopressors (p=0.033) were the only 
variables associated with mortality. The comparison of echocardiographic variables is shown in Table 2. Patients who 
died had significantly increased right atrial (RA) indexed volume (p=0.010) and lower MAPSE (p=0.006). There were 
trends towards lower LV EF and tricuspid annular excursion (TAPSE) in those who died. Among laboratory 
parameters, serum creatinine was significantly higher in those who died (p=0.032) [Supplementary Table 1]. 
Multivariable analysis was conducted using binary logistic regression incorporating variables significant on bivariate 
analysis. Shock requiring vasopressors (HR 9.2; 95% CI 1.4-59.3), MAPSE (HR 1.6; 95% CI 1.2-2.2), and RA indexed 
volume (HR 1.1; 95% CI 1.0-1.3) were found to be independently associated with mortality. MAPSE yielded an area 
under curve (AUC) of 0.72 with an optimal threshold of 1.0 cm by receiver operating characteristic curve analysis. 
The AUC for RA indexed volume was 0.61 with an optimal cutoff valve of 22.6 cm3.  When used in combination, RA 
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indexed volume and MAPSE enabled identification of high and lower risk groups. Mortality was 77% in the presence 
of either reduced MAPSE (<1.0 cm) or increased RA volume index (>22.6 cm3). Survival was 84% in those who had 
both preserved MAPSE, and no significant RA enlargement. 
MAPSE emerged as the only left heart parameter independently associated with increased mortality. Other 
parameters of left heart size and function were not significantly different between groups, although there was a 
trend towards lower EF in those who died. This suggests that MAPSE may enhance early assessment of LV 
myocardial injury in patients with severe COVID-19 infection. MAPSE is a validated measure of LV longitudinal 
function that likely correlates reasonably with longitudinal strain. Thus, in critically-ill patients where image quality is 
insufficient for accurate assessment of longitudinal strain, MAPSE may be a reasonable alternative. Additionally, RA 
enlargement was independently associated with mortality. In the setting of respiratory failure from COVID-19, RA 
enlargement may result from the combined effect of increasing pulmonary pressures, right ventricular systolic 
dysfunction, positive pressure ventilation, and fluid resuscitation. It is therefore not surprising that development of 
RA enlargement early in the hospital admission is a marker of later mortality.  Although our study did not confirm the 
association between mortality and RV dilation or dysfunction, there was a trend towards lower TAPSE in patients that 
died. 
 There has been significant effort to identify early predictors of mortality including using modalities such as 
point of care ultrasound (6,7). In our study population of critically-ill patients with COVID-19, the presence of either 
reduced MAPSE or RA enlargement was associated with high risk of in-hospital mortality while those who had 
preserved MAPSE, and no RA enlargement had a high in-hospital survival rate. This suggests in combination, MAPSE 
and RA size can successfully risk stratify patients with severe COVID-19 infection early in their hospital course and 
may enable early institution of aggressive therapies for high risk patients.  
The retrospective nature, small sample size and possible bias related to selective use of echocardiography 
are limitations of our investigation.  Our findings suggest that assessment of longitudinal systolic function of the left 
heart using MAPSE in addition to evaluation of the right heart may yield accurate information for risk stratification of 
patients with severe COVID-19 infection early in their hospital course. Larger, prospective studies are needed to 
further define parameters that predict outcome in this disease.  
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Table 1. Baseline demographics, medical comorbidities, and clinical course of the overall cohort and each study group 
Table 1.  All Patients Alive Dead P 
No. of Patients 68 46 (68%) 22 (32%)  
Demographic Information n (%)/mean ± SD n (%)/mean ± SD n (%)/mean ± SD  
Age, years (range) 64±14 (31-87) 61±15 (31-86) 70±10 (47-87) 0.018* 
Body Mass Index, kg/m2 34.9±10.9 33.3±10.3 38.2±11.0 0.075 
Sex 
Male 
Female 
 
41 (60) 
27 (40) 
 
29 (63) 
17 (37) 
 
12 (55) 
10 (45) 
0.503 
Race 
Black 
White 
Other 
 
36 (53) 
28 (41) 
4 (6) 
 
24 (52) 
19 (41) 
3 (7) 
 
12 (55) 
9 (41) 
1 (5) 
0.944 
Hypertension 47 (69) 31 (67) 16 (73) 0.656 
Dyslipidemia 41 (60) 26 (57) 15 (68) 0.358 
Diabetes Mellitus 26 (38) 18 (39) 8 (36) 0.826 
Tobacco Use 22 (32) 16 (35) 6 (27) 0.536 
Coronary Artery Disease 18 (26) 12 (26) 6 (27) 0.917 
Congestive Heart Failure 13 (19) 10 (22) 3 (14) 0.427 
Chronic Kidney Disease 11 (16) 9 (20) 2 (9) 0.272 
COPD 12 (18) 8 (17) 4 (18) 0.936 
Asthma 10 (15) 5 (11) 5 (23) 0.196 
Clinical Information     
Organ Failure 
Mechanical Ventilation 
Shock Requiring Vasopressor 
Renal Replacement Therapy 
 
66 (97) 
47 (69) 
15 (22) 
 
45 (98) 
28 (61) 
8 (17) 
 
21 (95) 
19 (86) 
7 (32) 
 
0.588 
0.033* 
0.180 
ICU Days 13±8 14±8 10±6 ------ 
Hospital Days 18±9 21±8 11±5 ------ 
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*Represents statistical significance with P < 0.05.  
†SD, standard deviation; COPD, chronic obstructive pulmonary disease. 
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Table 2. Echocardiogram parameters of the entire cohort and a comparison between patients surviving and patients 
that died 
Table 2.  Cohort Alive  Dead P 
No. of Patients 68 46 (68%) 22 (32%)  
Echocardiogram Parameter Mean ± SD  Mean ± SD Mean ± SD  
LV Diastolic Volume (mL) 103±34 107±38 95±24 0.186 
LV Systolic Volume (mL) 48±24 48±24 49±24 0.908 
LV Ejection Fraction (%) 55±14 56±12 50±16 0.089 
LVOT VTI (cm) 18±4 18±4 17±5 0.263 
IVS thickness (cm) 1.1±0.2 1.1±0.2 1.1±0.2 0.886 
LVPW thickness (cm) 1.0±0.2 1.0±0.2 1.1±0.2 0.719 
LV Diastolic Diameter (cm) 4.6±0.8 4.7±0.8 4.6±0.8 0.699 
LV Systolic Diameter (cm) 3.2±0.8 3.2±0.8 3.3±1.0 0.993 
LV Basal Fractional Shortening  0.30±0.11 0.31±0.10 0.28±0.14 0.407 
LA volume (indexed for BSA) (mL/m2) 21.7±9.7 21.4±7.7 22.2±12.9 0.767 
LA AP diameter (cm) 3.6±0.7 3.7±0.7 3.4±0.7 0.057 
RV Basal Diameter (cm) 3.9±0.8 3.8±0.7 4.0±0.9 0.484 
TAPSE (cm) 2.0±0.4 2.1±0.4 1.9±0.4 0.084 
RV Diastolic Area (indexed for BSA) (cm2/m2) 10.2±3.1 10.1±2.8 10.6±3.6 0.566 
RV Systolic Area (indexed for BSA) (cm2/m2) 6.4±2.5 6.2±1.9 7.0±3.2 0.260 
RV FAC (%) 37.7±9.2 38.8±8.8 35.8±9.9 0.268 
RA volume (indexed for BSA) (mL/m2) 19.6±10.9 17.0±7.0 24.3±14.8 0.010* 
RVOT VTI (cm) 14.3±4.1 14.4±3.9 14.0±4.8 0.778 
E/e’ lateral 8.9±5.0 9.3±5.5 8.1±3.5 0.395 
E/e’ septal 10.2±3.7 10.2±3.3 10.3±4.4 0.951 
E/e’ (Avg) (cm/s) 9.7±4.3 10.0±4.6 9.1±3.8 0.441 
TR Jet Velocity (cm/s) 255±52 256±49 254±56 0.933 
RAP (mmHg) 8.7±5.4 7.8±5.3 10.3±5.2 0.103 
RVSP (mmHg) 34.0±12.0 31.3±13.2 37.1±9.9 0.213 
8 
PVR (WU) 2.2±0.9 2.1±0.9 2.5±0.8 0.274 
MAPSE (cm) 
Lateral 
Septal 
Averaged 
1.3±0.3 
1.0±0.3 
1.1±0.3 
1.3±0.3 
1.1±0.2 
1.2±0.3 
1.1±0.3 
0.9±0.2 
1.0±0.3 
0.004* 
0.008* 
0.006* 
*Represents statistical significance with P < 0.05.
†SD, standard deviation; LV, left ventricle; LVOT, left ventricular outflow tract; VTI, velocity time integral; IVS, 
interventricular septum; LVPW, left ventricular posterior wall; LA, left atrium; BSA, body surface area; RV, right 
ventricle; TAPSE, tricuspid annular plane systolic excursion; FAC, fractional area change; RA, right atrium; RVOT, 
right ventricular outflow tract; E, peak transmitral early diastolic inflow velocity; e′, peak early diastolic longitudinal 
mitral annular velocity determined by color TDI; TR, tricuspid regurgitation; RAP, right atrial pressure; RVSP, right 
ventricular systolic pressure; PVR, pulmonary vascular resistance; MAPSE, mitral annular plane systolic excursion 
